Many children in Singapore may not be vaccinated according to the national recommended immunization schedule, with maternal age, ethnicity, household income, and number of siblings among the factors influencing non-adherence, according to findings from the GUSTO* study.
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
Pharmaceutical industry representatives highlighted lesser-known career opportunities for licensed pharmacists at the recent Pharmaceutical Industries Pharmacists Insights 3.0 (PIPI 3.0) symposium in Petaling Jaya.
New drug applications approved by US FDA as of 01 - 15 February 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.
Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).
A US-based retrospective cohort study has shown no difference in the rates of mortality and cardiovascular disease (CVD) with initiation and continuous use of either analogue or human insulin in insulin-naïve adults with type 2 diabetes (T2D).
Dose escalation of ustekinumab appears to be an effective option for Crohn’s disease (CD) patients with luminal and perianal manifestations who were nonresponsive to previous therapies, according to a study presented at the Crohn's & Colitis Congress (CCC) 2020.
The humanized monoclonal antibody mirikizumab appears to reduce bowel movement urgency among patients with moderate to severely active ulcerative colitis (UC), according to a study presented at the Crohn’s and Colitis Congress 2020.
The combination of the immunomodulatory agent lenalidomide and the monoclonal antibody rituximab (R2) proved effective and safe in individuals ≥70 years with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL) compared with rituximab alone, according to a post hoc analysis of the phase III AUGMENT* trial presented at ASH 2019.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Adding epoetin alfa (EA) to lenalidomide significantly helps achieve major erythroid response (MER) in patients with erythropoietin (Epo)-refractory, lower risk non-deletion 5q (non-del(5q)) myelodysplastic syndrome (MDS) compared with lenalidomide alone, according to the final results of the E2905* trial presented at ASH 2019.